Treat-to-target in immunology: what it means for prescribing and reimbursement

What treat-to-target is

Treat-to-target is a clinical management framework with three components:

• A defined target (clinical remission, low disease activity, mucosal healing, or a similar measurable state, depending on disease)
• A defined assessment cadence (typically 3 to 6 months)
• A defined action when the target is not achieved (escalate dose, switch therapy, or add combination)

The framework was developed in rheumatoid arthritis (DAS28 remission as the original target), generalised across rheumatology, and is now applied in IBD (mucosal healing as a target alongside symptom control) and psoriasis (PASI 90 or absolute PASI thresholds as targets).

Why it matters for prescribing and reimbursement

Treat-to-target shapes prescribing at three points:

• Initial therapy choice: assets with the strongest evidence on achieving the target define the first-line decision
• Assessment cadence: the cadence imposes infrastructure requirements (visit frequency, monitoring labs, imaging in some indications) that are themselves a commercial input
• Switching trigger: a defined target plus a defined assessment cadence creates a defensible switching trigger that prior authorisation systems can engage with cleanly

Reimbursement systems are increasingly aligning with treat-to-target. PA criteria that require documentation of inadequate response under treat-to-target assessment are more durable than criteria that rely on subjective clinician judgement. Outcomes-based managed-access agreements use treat-to-target endpoints as the contractual measurement.

Where it is working and where it is not

Treat-to-target is working where the target is well-defined, the assessment infrastructure is reliable, and the therapy options are sufficient. Rheumatoid arthritis is the strongest example: DAS28 is well-validated, joint counts are routine, and the biologic class is broad enough that switching is operationally feasible.

Treat-to-target is harder where:

• The target is not well-defined (psoriatic arthritis remains contested on whether MDA, DAPSA or composite measures should be the target)
• The assessment infrastructure is not in place (rural and community settings often lack the imaging or specialist-clinic access for IBD mucosal healing assessment)
• The therapy options are insufficient (third-line and fourth-line in any indication where the patient has cycled through major mechanisms)

What this means for commercial teams

Treat-to-target is not optional. It is the increasingly dominant prescribing frame across immune-mediated disease and is being encoded into reimbursement architectures. Commercial teams that engage with it strategically (target-anchored evidence packages, assessment-infrastructure support, treat-to-target-aligned PA submissions) operate within the prescribing reality. Commercial teams that do not face friction at every step of the access pathway.